ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Sponsor: Amgen
A PHASE3 clinical study on Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Amgen and has accumulated 11 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE3
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
May 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahilyanagar, India , Ancona, Italy , Ballarat, Australia , Bardejov, Slovakia , Beersheba, Israel , Beijing, China , Belfast, United Kingdom , Besançon, France , Box Hill, Australia , Boynton Beach, United States and 115 more locations